Pollens - grasses, timothy phleum pratense - Biologic Drug Details

Summary for pollens - grasses, timothy phleum pratense

Tradenames:	1
High Confidence Patents:	0
Applicants:	5
BLAs:	5
Suppliers: see list	4

Pharmacology for pollens - grasses, timothy phleum pratense

Physiological Effect	Cell-mediated Immunity Increased Histamine Release Increased IgG Production
Established Pharmacologic Class	Standardized Pollen Allergenic Extract Non-Standardized Pollen Allergenic Extract
Chemical Structure	Allergens Pollen

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for pollens - grasses, timothy phleum pratense Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for pollens - grasses, timothy phleum pratense Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for pollens - grasses, timothy phleum pratense Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for the Biologic Drug: Pollens – Grasses, Timothy (Phleum pratense)

Last updated: February 24, 2026

What Is the Current Market for Timothy Pollen-Based Biologics?

The biologic market targeting pollens like Timothy grass (Phleum pratense) primarily focuses on allergy immunotherapy (AIT). Timothy grass pollen extract is used to treat allergic rhinitis and allergic asthma. It is available in subcutaneous (SCIT) and sublingual (SLIT) formulations.

Worldwide, the allergy immunotherapy market is valued at approximately $4.4 billion in 2022, with grass pollen extracts representing the largest segment. The market for Timothy grass pollen-specific immunotherapy accounts for roughly 40% of grass pollen AIT sales, making it a significant player within the broader allergy biologics field.

What Are the Market Drivers and Barriers?

Drivers:

• Increasing prevalence of allergic rhinitis globally, projected to reach approximately 25-30% of the population in developed countries.
• Growing awareness of immunotherapy as a long-term solution over symptomatic treatments.
• Advancements in biologic formulations, including standardized extracts and novel delivery systems.
• Regulatory approval of new biologic products enhances market penetration.

Barriers:

• High development and manufacturing costs for biologic allergy therapies.
• Variability in patient response to pollen extracts.
• Stringent regulatory pathways in different regions, affecting time-to-market.
• Competition from antihistamines and corticosteroids, which are less costly and more accessible.

What Is the Financial Trajectory for Timothy Pollen-Based Biologics?

Market Revenue:
Forecasts project the allergy biologic market to grow at a CAGR of approximately 8.5% from 2022 to 2030. Timothy grass pollen-specific products are expected to benefit from this growth due to their dominant market share.

Product Development Costs:
Biologic allergy treatments involve substantial R&D investments, often exceeding $150 million per product, inclusive of clinical trials, manufacturing scale-up, and regulatory submission.

Pricing Trends:
Annual treatment costs for Timothy grass pollen immunotherapy range between $600 and $1,200, depending on formulation and region. SLIT products generally carry lower costs than SCIT due to convenience and reduced clinical administration expenses.

Market Penetration & Revenue Sharing:
Major players like Merck, Stallergenes Greer, ALK, and Circassia dominate the market. Newly approved biologics or biosimilars could capture up to 15% market share within five years of launch, translating into hundreds of millions of dollars in annual revenue.

What Are the Key Market Players and Their Strategies?

• Stallergenes Greer: Focuses on standardized grass pollen extracts, expanding into sublingual formulations.
• ALK: Invests heavily in developing patient-friendly delivery systems, including pre-filled SLIT tablets.
• Circassia: Emphasizes convenience with once-daily sublingual tablets for grass pollen allergy.

Most companies prioritize expanding regional access, conducting phase III trials for new formulations, and securing regulatory approvals to accelerate market entry.

What Is the Regulatory Environment?

US Food and Drug Administration (FDA) approval involves demonstrating safety, efficacy, and consistency of biologic extracts. The European Medicines Agency (EMA) follows similar standards, with some regions adopting accelerated pathways for allergen immunotherapies.

Regulatory timelines span approximately 2-4 years, influenced by clinical trial outcomes, manufacturing compliance (Good Manufacturing Practices), and post-market surveillance.

Summary of Financial Outlooks

Year	Market Size (USD billions)	Growth Rate (CAGR)	Key Factors
2022	4.4	N/A	Existing products, demand surge
2025	6.2	8.7%	New product launches, expansion
2030	9.4	8.5%	Broader adoption, biosimilars

Investment in R&D, market expansion, and regulatory navigation will shape the profitability of Timothy grass pollen biologics.

What Are the Future Market Opportunities?

• Development of novel delivery systems to improve patient adherence.
• Biosimilars and follow-on biologics to reduce treatment costs.
• Expansion into emerging markets with rising allergy prevalence.
• Integration with digital health tools for monitoring and personalized treatment.

Key Takeaways

• The Timothy grass pollen biologic segment is a significant part of the allergy immunotherapy market, growing at an estimated CAGR of 8.5% through 2030.
• Market growth is driven by increased allergy prevalence, technological advancements, and regulatory progress.
• High development costs and market competition challenge new entrants.
• Current treatment costs range from $600 to $1,200 annually; market incumbents hold substantial revenue share.
• Future growth depends on innovation, biosimilar entry, and regional expansion.

FAQs

1. How does Timothy grass pollen biologic therapy compare with other allergy treatments?
Biologics, like pollen extracts, offer long-term disease modification, unlike antihistamines which provide symptom relief. They require longer treatment periods but are effective for persistent allergy sufferers.

2. What are the main risks associated with biologic pollen treatments?
Potential risks include allergic reactions, rare anaphylaxis, and variability in patient response. Safety profiles are well established with approved therapies.

3. Are biosimilars entering the Timothy grass pollen biologic market?
Yes. Biosimilars are emerging as cost-effective alternatives after patent expirations. Their entry could impact pricing and market share.

4. Which regions show the fastest growth potential?
Asia-Pacific and Latin America are experiencing rapid increases in allergy prevalence, presenting significant growth opportunities for biologics.

5. What are the regulatory hurdles for new biologic pollen therapies?
Regulatory agencies require demonstration of safety, consistent manufacturing, and efficacy through extensive clinical trials, typically spanning 2-4 years.

---

References

1. GlobalData. (2022). Allergy immunotherapy market analysis.
2. MarketWatch. (2023). Biologic allergy treatment sales forecast.
3. U.S. Food and Drug Administration. (2022). Guide for allergen immunotherapy approval.
4. European Medicines Agency. (2022). Regulatory guidelines for allergy biologics.
5. Grand View Research. (2023). Allergy immunotherapy market size and trends.